Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Signifor (Pasireotide) – Treatment for Cushing’s Disease

Drug (Brand / Generic)

Signifor / SOM230 / Pasireotide

Company / Licensee

Novartis

Therapy Class

Somatostatin analogue

Current Indication

Cushing’s disease

Market Sector

Endocrinology

Development Status

Approved in Europe
Expand
Close
Close
Close

Go Top